Determination of plicamycin in plasma by radioimmunoassay

Ther Drug Monit. 1992 Jun;14(3):255-60. doi: 10.1097/00007691-199206000-00013.

Abstract

This article describes a method for the determination of plicamycin in plasma by radioimmunoassay. The anti-plicamycin antibody was produced against a plicamycin-bovine serum albumin conjugate prepared by using diazotized p-aminobenzoic acid as a cross-linker. The radiolabeled ligand, 125I-plicamycin, was prepared by the chloramine-T method. The linear plicamycin concentration range was 7-400 ng/ml. The coefficients of variation for intra- and interday variabilities were 7.5 and 15%, respectively. No interference was observed from either the structurally related chromomycin A or concomitantly used drugs hydroxyurea or allopurinol. With this method of testing, plicamycin levels in plasma could be determined in patients receiving small (0.85-1.0 mg/m2) therapeutic plicamycin doses. Preliminary pharmacokinetic data in humans indicate that the plasma drug disappearance curve was biphasic with a mean elimination half-life of 10.6 +/- 1.7 h, total clearance rate of 11.1 +/- 0.4 ml/min/m2, and area under the plasma drug concentration-time curve of 1,289-1,546 ng-h/ml. This assay method is clinically useful for pharmacokinetic studies of plicamycin and may be helpful in the design of rational therapeutic drug trials.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antibody Specificity
  • Cross Reactions
  • Half-Life
  • Humans
  • Infusions, Intravenous
  • Iodine Radioisotopes
  • Leukemia, Myeloid / drug therapy
  • Leukemia, Myeloid / metabolism
  • Plicamycin / analogs & derivatives*
  • Plicamycin / blood
  • Plicamycin / immunology
  • Plicamycin / pharmacokinetics
  • Radioimmunoassay

Substances

  • Iodine Radioisotopes
  • mithramycin A
  • Plicamycin